Announced a 5% increase with the May Dividend payment. Same active dates for previous dividend increases when it was under Abbott.
What Miles does with his personal money is his business. If Abbott bought the Deerpath Inn as a business investment than it becomes the business of the stockholders and the Board of Directors.
Go peddle your BS some where else. This is an Abbott investment board. If you think you are being taken advantage of, get out of the market.
The market finally woke up and realized that ABBV is not going to be first to market with a new Hep C drug, and at best they will only have a cocktail drug and the only way they are going to be able to compete with Gilead is by price.
Abbott has not been the parent for ABBV for the last year. I am certain that you may have meant past parent company. The companies separated into two different publicly traded companies on Jan. 1, 2013 and are independent of each other.
One of the poorest presentations that I have witnessed by both Miles White and Tom Freyman and the written comments to 4th quarter and total year results were even worse. Danced around many operational issues and had no good reason as to why they were bringing into the US $2 Billion (all of the 2014 Cash Flow from foreign operations) and paying US taxes on these funds. It looks on the surface that the reason is to buy back $2Billion (50million shares or 3%) of stock in order to help make 2014 EPS since Freyman made the statement in the conference that no good prospects for M&A activity on the horizon. If these two want any bonus dollars in 2014 than they need to get their act together. Looks like the analysts came away with the same take as I have.
Abt missed sales because: 1.) Diabetic sales neg. growth. 2.) Established Pharm Sales in mature markets (ie. Europe) show no growth. 3.) Pediatric sales in China, Vietnam and Saudi Arabia, have negatively been impacted in the 3rd and 4th Quarters. First and Second Qtr 2014 EPS are very low, and it looks like Abbott is bring into US 2014 foreign earnings and paying US taxes to buy back 3% of Abbott outstanding share in order to make 2014 EPS targets.
You are correct AbbVie did not exist in 2012, but there are pro-forma statements assuming the split had occurred.
Classhopper, I can understand why you may like ENTA, but this is an ABBV board. If we have any interest in ENTA we will do our own DD.